Floatz logo

Elesclomol

Fallopian Tube Clear Cell Adenocarcinoma

GOG FoundationSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Fallopian Tube Clear Cell Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
NRG Oncology
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2B

View all 27 →

Same molecule, other indications

Elesclomol is also rated in:

fallopian tube mucinous adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube endometrioid adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →